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OBJECTIVE: To study the incidence and cost of man-
agement of deep vein thrombosis (DVT), and to estimate
the cost avoidance due to prophylactic therapy in a group
of Hong Kong Chinese patients undergoing total hip
replacement (THR). METHOD: All Chinese patients
undergoing THR from November 98 to December 2001
at the Prince of Wales Hospital in Hong Kong were ret-
rospectively evaluated. In those patients who developed
DVT, the cost of management was estimated by identify-
ing the total healthcare resources used. The cost avoid-
ance of DVT by using prophylactic low-molecular-weight
heparin LMWH (nandroparin calcium) was estimated by
construction of a decision tree model. Sensitivity analysis
was performed to examine whether the results were
robust to changes in the key variables. The study was per-
formed from the perspective of a publicly funded hospi-
tal. RESULTS: A total of 90 Chinese patients underwent
THR surgery over the study period and their baseline
characteristics were comparable. Six had symptomatic
DVT, yet only three were conﬁrmed by Doppler ultra-
sonography. The incidence of symptomatic DVT in this
group of Hong Kong Chinese was therefore 3.33%. 
The treatment costs after THR surgery with or without
DVT per patient were HKD129,980 (119,740–
140,210) (median (25%,75%)) (1USD = 7.8HKD) and
HKD79,410 (73,860–84,960) respectively. The cost of
management of DVT without prophylaxis was
HKD53,570 (39,980–67,170) per patient. A close to
70% reduction in cost was possible if LMWH prophy-
laxis was used. CONCLUSION: The incidence of symp-
tomatic DVT in the present group of Hong Kong Chinese
patients after THR surgery was similar to that in the 
Caucasians. According to the decision-tree model, cost
avoidance appears to be possible by using LMWH for
prophylaxis of DVT in high-risk orthopaedic procedures.
Prophylactic antithrombotic therapy should be consid-
ered for routine use in THR surgery.
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OBJECTIVE: Cost-effectiveness analysis of treatments 
to reduce cholesterol concentration, blood pressure and
smoking for the primary prevention of coronary heart
disease in Catalonia (Spain) was assessed in this study.
METHODS: Cost-effectiveness was measured in terms of
met cost per life year gained (LYG), comparing costs and
beneﬁts from coronary heart disease in individuals aged
>30 years with hypercholesterolemia >200mg/dl, moder-
ate/severe (DBP > 105mmHg) and mild (DBP 95–104
mmHg) hypertension and smoking. Cost-effectiveness
ratios were calculated for 1998 using a 5% discount rate.
RESULTS: Cost-effectiveness ratios obtained in this study
ranged from €2,608 to €8,058 per LYG for smoking ces-
sation therapies, from €7,061 to €81,027 per LYG for
moderate/severe hypertension treatment, from €10,877 to
€126,990 per LYG for mild hypertension treatment, and
from €12,792 to €142,910 per LYG for dietary and phar-
maceutical treatment of hypercholesterolemia. Incremen-
tal cost-effectiveness analysis showed that lovastatin
(HMG-CoA reductase inhibitor) was more cost-effective
than cholestyramine (bile acid sequestrant) and gemﬁ-
brozil (ﬁbrate) in individuals with hypercholesterolemia,
hydrochlorothiazide (diuretic) and propranolol (beta-
adrenergic antagonist) were more cost-effective than 
captopril (angiotensin-converting-enzyme inhibitor), 
prazosin (alpha-adrenergic antagonist) and nifedipine
(calcium channel blocker) in individuals with moder-
ate/severe hypertension treatment, and hydrochloroth-
iazide and nifedipine were more cost-effective than
propranolol, prazosin and captopril in individuals with
mild hypertension treatment. CONCLUSION: When
resources for the primary prevention of coronary heart
disease are limited, the priority order based on cost-
effectiveness analysis was smoking cessation, hyperten-
sion treatment and hypercholesterolemia treatment.
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OBJECTIVES: To evaluate the pharmacoeconomics of
hawthorn-extract treatment of CHF at stage NYHA II, 
a prospective 3-year observational study has been con-
ducted since summer 1999. A cost-utility-analysis (CUA)
will compare hawthorn treatment (WS 1442 as mono- 
or add-on-therapy) to any other treatment option. The
results of two years of study conduct are presented.
METHODS: Open, non-randomized observational
cohort study with matched-pairs evaluation. The ﬁrst
cohort (Hawthorn-Cohort, HC) comprises patients
receiving hawthorn-extract therapy of CHF. In the second
cohort (Conventional-Cohort, CC) patients without
hawthorn but any other treatment were observed. In 217
study centres 952 patients were included (HC: 588; CC:
364). A number of 116 pairs were determined as sample
size necessary for evaluation. For measuring HRQL the
EuroQoL-5D was used. Matching criteria were derived
from demographic factors and clinical diagnosis. The per-
spective of the German statutory health insurance funds
was applied. RESULTS: 130 pairs could be established
under consideration of two-year data. Median direct costs
per year for HC amounted to €473 and for CC to €449.
This difference is not signiﬁcant (p = .218). Most impor-
